BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25518860)

  • 1. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
    Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
    Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
    Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.
    Rettenmaier TJ; Fan H; Karpiak J; Doak A; Sali A; Shoichet BK; Wells JA
    J Med Chem; 2015 Oct; 58(20):8285-8291. PubMed ID: 26443011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of SBF1 as an allosteric inhibitor targeting the PIF-pocket of 3-phosphoinositide-dependent protein kinase-1.
    Liu W; Li P; Mei Y
    J Mol Model; 2019 Jun; 25(7):187. PubMed ID: 31197600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turning a protein kinase on or off from a single allosteric site via disulfide trapping.
    Sadowsky JD; Burlingame MA; Wolan DW; McClendon CL; Jacobson MP; Wells JA
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6056-61. PubMed ID: 21430264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments.
    Stockman BJ; Kothe M; Kohls D; Weibley L; Connolly BJ; Sheils AL; Cao Q; Cheng AC; Yang L; Kamath AV; Ding YH; Charlton ME
    Chem Biol Drug Des; 2009 Feb; 73(2):179-88. PubMed ID: 19207420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.
    Busschots K; Lopez-Garcia LA; Lammi C; Stroba A; Zeuzem S; Piiper A; Alzari PM; Neimanis S; Arencibia JM; Engel M; Schulze JO; Biondi RM
    Chem Biol; 2012 Sep; 19(9):1152-63. PubMed ID: 22999883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patent update on PDK1 inhibitors (2015-present).
    Sestito S; Rapposelli S
    Expert Opin Ther Pat; 2019 Apr; 29(4):271-282. PubMed ID: 30897008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
    Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
    J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma.
    Sestito S; Daniele S; Nesi G; Zappelli E; Di Maio D; Marinelli L; Digiacomo M; Lapucci A; Martini C; Novellino E; Rapposelli S
    Eur J Med Chem; 2016 Aug; 118():47-63. PubMed ID: 27123901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site.
    Biondi RM; Komander D; Thomas CC; Lizcano JM; Deak M; Alessi DR; van Aalten DM
    EMBO J; 2002 Aug; 21(16):4219-28. PubMed ID: 12169624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-(3-Oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept.
    Wilhelm A; Lopez-Garcia LA; Busschots K; Fröhner W; Maurer F; Boettcher S; Zhang H; Schulze JO; Biondi RM; Engel M
    J Med Chem; 2012 Nov; 55(22):9817-30. PubMed ID: 23106316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemical diversity and structure-based discovery of allosteric modulators for the PIF-pocket of protein kinase PDK1.
    Xu X; Chen Y; Fu Q; Ni D; Zhang J; Li X; Lu S
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):361-374. PubMed ID: 30734603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric Regulation of Protein Kinases Downstream of PI3-Kinase Signalling.
    Leroux AE; Gross LZF; Sacerdoti M; Biondi RM
    Adv Exp Med Biol; 2019; 1163():279-311. PubMed ID: 31707708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.
    Bobkova EV; Weber MJ; Xu Z; Zhang YL; Jung J; Blume-Jensen P; Northrup A; Kunapuli P; Andersen JN; Kariv I
    J Biol Chem; 2010 Jun; 285(24):18838-46. PubMed ID: 20385558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1.
    Hindie V; Stroba A; Zhang H; Lopez-Garcia LA; Idrissova L; Zeuzem S; Hirschberg D; Schaeffer F; Jørgensen TJ; Engel M; Alzari PM; Biondi RM
    Nat Chem Biol; 2009 Oct; 5(10):758-64. PubMed ID: 19718043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.
    Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1.
    Hindie V; Lopez-Garcia LA; Biondi RM
    Methods Mol Biol; 2012; 928():133-41. PubMed ID: 22956138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound.
    Zhang H; Neimanis S; Lopez-Garcia LA; Arencibia JM; Amon S; Stroba A; Zeuzem S; Proschak E; Stark H; Bauer AF; Busschots K; Jørgensen TJ; Engel M; Schulze JO; Biondi RM
    Chem Biol; 2014 Jun; 21(6):754-65. PubMed ID: 24836908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases.
    Arencibia JM; Pastor-Flores D; Bauer AF; Schulze JO; Biondi RM
    Biochim Biophys Acta; 2013 Jul; 1834(7):1302-21. PubMed ID: 23524293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.